Related references
Note: Only part of the references are listed.Cancer vaccine strategies using self-replicating RNA viral platforms
Gabrielle P. Dailey et al.
CANCER GENE THERAPY (2023)
Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer A Phase 1 Nonrandomized Clinical Trial
Mary L. Disis et al.
JAMA ONCOLOGY (2023)
Molecular Pathways and Mechanisms of HER2 in Cancer Therapy
Kanwal P. S. Raghav et al.
CLINICAL CANCER RESEARCH (2023)
A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells
Edward Seung et al.
NATURE (2022)
Breast Cancer Vaccines: Disappointing or Promising?
Si-Yuan Zhu et al.
FRONTIERS IN IMMUNOLOGY (2022)
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
Eleonora Nicolo et al.
CANCER TREATMENT REVIEWS (2022)
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
J. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial
Jens Huober et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Breast Cancer, Version 3.2022
William J. Gradishar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)
Adenoviral-based vaccine promotes neoantigen-specific CD8+ T cell stemness and tumor rejection
Anna Morena D'Alise et al.
SCIENCE TRANSLATIONAL MEDICINE (2022)
Role of immunotherapy in metastatic EGFRm NSCLC: Is it relevant?
Boman Dhabhar et al.
INDIAN JOURNAL OF CANCER (2022)
Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response
Mame Daro-Faye et al.
WORLD JOURNAL OF UROLOGY (2021)
A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers.
Shubham Pant et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma
Zhuting Hu et al.
NATURE MEDICINE (2021)
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial
Hope S. Rugo et al.
JAMA ONCOLOGY (2021)
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
Sherko Kuemmel et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics
Kamal S. Saini et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2021)
FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer
Jennifer J. Gao et al.
CLINICAL CANCER RESEARCH (2021)
Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells
Faezzah Baharom et al.
NATURE IMMUNOLOGY (2021)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia The PEONY Phase 3 Randomized Clinical Trial
Zhimin Shao et al.
JAMA ONCOLOGY (2020)
Atezolizumab for the treatment of breast cancer
Sangeetha M. Reddy et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors
Julie M. Collins et al.
ONCOLOGIST (2020)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Sandra M. Swain et al.
LANCET ONCOLOGY (2020)
Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial
A. M. M. Eggermont et al.
ANNALS OF ONCOLOGY (2020)
Amplifying RNA Vaccine Development
Deborah H. Fuller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer
Erika J. Crosby et al.
CLINICAL CANCER RESEARCH (2020)
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
Leisha A Emens et al.
LANCET ONCOLOGY (2020)
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial
Sherene Loi et al.
LANCET ONCOLOGY (2019)
Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade
Anna Morena D'Alise et al.
NATURE COMMUNICATIONS (2019)
Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response
Krithika N. Kodumudi et al.
FRONTIERS IN IMMUNOLOGY (2019)
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma (vol 175, 998.e1 , 2018)
Moshe Sade-Feldman et al.
CELL (2019)
Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study
Erika J. Crosby et al.
CLINICAL CANCER RESEARCH (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils
Louise W. Treffers et al.
FRONTIERS IN IMMUNOLOGY (2019)
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Jiani Wang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis
Li-Chung Tsao et al.
JCI INSIGHT (2019)
The less-is-more in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity
Natasha A. Pereira et al.
MABS (2018)
Correlates of immune and clinical activity of novel cancer vaccines
Sjoerd H. van der Burg
SEMINARS IN IMMUNOLOGY (2018)
Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells
Hans H. Oberg et al.
FRONTIERS IN IMMUNOLOGY (2018)
Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer The SOLD Randomized Clinical Trial
Heikki Joensuu et al.
JAMA ONCOLOGY (2018)
44PGlobal clinical trials validating bioequivalence with China-manufactured trastuzumab biosimilar, HLX02, and trastuzumab
Q Zhang et al.
ANNALS OF ONCOLOGY (2018)
Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages
Shicheng Su et al.
CELL (2018)
Macrophage Checkpoint Blockade in Cancer - Back to the Future
Alberto Mantovani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 thorn Breast Cancer Metastasis to the Brain
Saul J. Priceman et al.
CLINICAL CANCER RESEARCH (2018)
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
Veronique Dieras et al.
LANCET ONCOLOGY (2017)
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2017)
Driving better and safer HER2-specific CARs for cancer therapy
Xianqiang Liu et al.
ONCOTARGET (2017)
Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy
Yuting Huang et al.
JOURNAL OF THORACIC DISEASE (2017)
Herceptin Enhances the Antitumor Effect of Natural Killer Cells on Breast Cancer Cells Expressing Human Epidermal Growth Factor Receptor-2
Xiao Tian et al.
FRONTIERS IN IMMUNOLOGY (2017)
Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis
Wouter Hendrickx et al.
ONCOIMMUNOLOGY (2017)
Plant viral nanoparticles-based HER2 vaccine: Immune response influenced by differential transport, localization and cellular interactions of particulate carriers
Sourabh Shukla et al.
BIOMATERIALS (2017)
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors
Steven A. Limentani et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer
Giuseppe Curigliano et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Immunotherapy for breast cancer: past, present, and future
Alison Spellman et al.
CANCER AND METASTASIS REVIEWS (2016)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
Luca Gianni et al.
LANCET ONCOLOGY (2016)
Dendritic Cells and Cancer Immunity
Alycia Gardner et al.
TRENDS IN IMMUNOLOGY (2016)
Acquired resistance to immunotherapy and future challenges
Nicholas P. Restifo et al.
NATURE REVIEWS CANCER (2016)
Adjuvant HER2/neu peptide cancer vaccines in breast cancer
Guy T. Clifton et al.
IMMUNOTHERAPY (2015)
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
Huimin Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wei Wang et al.
FRONTIERS IN IMMUNOLOGY (2015)
Adoptive T Cell Immunotherapy for Cancer
Karlo Perica et al.
RAMBAM MAIMONIDES MEDICAL JOURNAL (2015)
Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients
E. A. Mittendorf et al.
ANNALS OF ONCOLOGY (2014)
The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response
Erika J. Schneble et al.
IMMUNOTHERAPY (2014)
The immune system and response to HER2-targeted treatment in breast cancer
Giampaolo Bianchini et al.
LANCET ONCOLOGY (2014)
A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer
Gang Chen et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity
Henri-Alexandre Michaud et al.
ONCOIMMUNOLOGY (2014)
Construction and evaluation of a novel humanized HER2-specific chimeric receptor
Meili Sun et al.
BREAST CANCER RESEARCH (2014)
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Pierre G. Coulie et al.
NATURE REVIEWS CANCER (2014)
Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives
A. Milani et al.
ANNALS OF ONCOLOGY (2013)
Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology
Michael Kalos et al.
IMMUNITY (2013)
Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1
Stamatis Vassilaros et al.
IMMUNOTHERAPY (2013)
Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors
Claudia Marcela Diaz-Montero et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells
Kristine Kleivi Sahlberg et al.
MOLECULAR ONCOLOGY (2013)
Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade
Leisha A. Emens
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
Filamentous Bacteriophage Fd as an Antigen Delivery System in Vaccination
Antonella Prisco et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)
Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling
Scott Wilkie et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells
Timothy Kute et al.
ONCOIMMUNOLOGY (2012)
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Evan J. Lipson et al.
CLINICAL CANCER RESEARCH (2011)
Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models
Yoriko Yamashita-Kashima et al.
CLINICAL CANCER RESEARCH (2011)
Revisiting human natural killer cell subset function revealed cytolytic CD56dimCD16+ NK cells as rapid producers of abundant IFN-γ on activation
Andrea De Maria et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
SaeGwang Park et al.
CANCER CELL (2010)
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial
Hakan Norell et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors
Y. Gao et al.
CANCER GENE THERAPY (2009)
Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
Leisha A. Emens et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The Other signaling of trastuzumab: Antibodies are immunocompetent drugs
Luca Gianni
JOURNAL OF CLINICAL ONCOLOGY (2008)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion
Brian J. Czerniecki et al.
CANCER RESEARCH (2007)
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors
Hazem Ghebeh et al.
NEOPLASIA (2006)
Effect of dose on immune response in patients vaccinated with an HER-2/neu intracellular domain protein-based vaccine
ML Disis et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer
P Kauraniemi et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Share Paper
